Most Read

NBE-Therapeutics is engaged in developing antibody-drug conjugates (ADCs) and advancing targeted cancer therapies by using its immune stimulatory iADC platform. NBE-002, the company’s lead compound, is presently in

The BNT162b2 vaccine has been granted authorisation under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19. Canada is

The interim analysis for the efficacy of the AZD1222 vaccine candidate was based on 11,636 volunteers accruing 131 symptomatic infections from the phase 3 trials in the UK

Sotorasib, which is claimed to be the first KRAS G12C inhibitor to enter the clinic, is being assessed in the wide clinical programme examining 10 combinations with global

The phase 2 segment has been designed to assess the safety and immunogenicity of INO-4800 Covid-19 vaccine candidate to confirm the dose for the subsequent efficacy assessment as

Via its affiliates, the investor Sino Biopharmaceutical has invested around $500m in exchange for about 15% of the total equity interest of Sinovac LS. Earlier to the announcement

HMR59 is being developed to administer as a one-time, outpatient and intravitreal injection to protect vision in patients with geographic atrophy, a late-stage and severe form of age-related

PRA Health Sciences, a clinical research organisation (CRO) selected by Appili, will conduct the trial at 47 outpatient sites. Avigan, which is an antiviral in oral tablet form

The BNT162b2 mRNA vaccine is said to be the first in the world to secure EUA status to fight against Covid-19. The status was provided by the UK